The FDA granted 2 Fast Track designations to the cavrotolimod for 2, including in combination with anti-PD-1 therapy in patients with locally advanced or metastatic Merkel cell carcinoma who are refractory to prior anti-PD-1 blockade and in combination with anti-PD-1/PD-L...
Fast track designation has been granted by the FDA to Deltacel with low-dose radiation for pretreated metastatic non–small cell lung cancer.
Tamibarotene plus azacitidine and venetoclax has received FDA fast track designation for newly diagnosed, unfit, RARA-overexpressed AML. FDA The FDA has granted fast track designation to tamibarotene in combination with azacitidine (Vidaza) and venetoclax (Venclexta) for the ...
The FDA has granted fast track designation to the PD-1/IL2α bispecific antibody fusion protein IBI363 as monotherapy for the treatment of patients with unresectable locally advanced or metastatic melanoma, excluding choroidal melanoma, that has progressed after 1 o...
An abstract is unavailable.DiGiulioSarah
Preliminary phase 1/2 trial (NCT05914116) data indicate the drug's efficacy and manageable toxicity. A fast track designation has been granted from the FDA to BNT324/DB-1311, an ADC, for the treatment of patients with unresectable advanced or metastatic CRPC who have progressed on or after ...
SynKIR-110, which received fast track designation from the FDA, is currently under investigation as treatment for patients with mesothelioma in the phase 1 STAR-101 trial. The FDA has granted fast track designation to the investigational agent SynKIR-110 for the treatment of patients wi...
The fast track designation will expedite the clinical development of the asset for melanoma treatment. Credit: yanishevska/Shutterstock. The US Food and Drug Administration (FDA) has granted its fast track designation toInnovent Biologics‘ IBI363, a PD-1/IL-2α-biasbispecific antibody fusion prot...
The FDA has granted a fast track designation to SYNC-T SV-102, an investigational therapy for patients with metastatic castrate-resistant prostate cancer (mCRPC), according to a news release from Syncromune, the developer of the agent.1
/PRNewswire/ -- Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ANPD001 for the...